Frontier Group Holdings (ULCC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Frontier Group Holdings Q1 twenty twenty one Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I wo ...

Cohu (COHU) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to Cohu's First Quarter twenty twenty five Financial Results Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conferenc ...

Financial Data and Key Metrics Changes - Total revenue for the first quarter was $52.4 million, representing a 25% growth from the same period last year [19] - MRD revenue grew 34% year-over-year to $43.7 million, with clinical and pharma contributions of 65% and 35% respectively [19] - Sequencing gross margin improved by 17 percentage points year-over-year to 62% [6][21] - Operating expenses decreased by 9% to $82 million, driven by lower R&D spending [21] - Cash burn for the quarter was $23 million, a 38% improvement compared to the same period last year [6] Business Line Data and Key Metrics Changes - ClonoSEQ clinical revenue grew 55% year-over-year, with test volume reaching over 23,000, a 36% increase [8] - Blood-based testing contributed 44% of MRD tests in the US, up from 39% a year ago [9] - MRD Pharma revenue grew 11% year-over-year, with $4.5 million recognized in regulatory milestones [12] - Immune medicine revenue was $8.7 million, down 6% from a year ago, primarily due to a decrease in Genentech amortization [20] Market Data and Key Metrics Changes - The number of ordering healthcare providers grew 31% year-over-year, now exceeding 3,400 [10] - EMR integrations accelerated, with 27 live integrations including five of the top 10 accounts [10] - The contribution of DLBCL and MCL in MRD tests increased to 12% from 10% a year ago [9] Company Strategy and Development Direction - The company is focused on increasing the lifetime value of each clonoSEQ Medicare patient and expanding its market presence in blood-based testing [6][14] - Strategic goals include achieving over 45% of clonoSEQ testing done in blood, launching Onco EMR with Flatiron, and beginning phase one testing with NeoGenomics [14] - The company aims to be adjusted EBITDA positive in the second half of the year [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving raised full-year guidance due to strong first-quarter performance and sustained momentum [24] - The company anticipates approximately 30% growth in clonoSEQ test volumes for 2025 compared to 2024 [22] - Management noted minimal exposure to tariffs and NIH funding pressures, highlighting a solid cash position of $233 million [7] Other Important Information - The company is raising its full-year MRD revenue guidance to a range of $180 million to $190 million [22] - Operating expense guidance has been lowered to a range of $335 million to $345 million [23] - Cash burn guidance has also been reduced to a range of $50 million to $60 million [23] Q&A Session Summary Question: Specific indications seeing growth and contribution trends - Management noted strong sequential growth across all indications, particularly in lymphoma indications like DLBCL and MCL [26][27] Question: Updates on EMR integration and growth quantification - Management reported significant growth in accounts that have been live for at least a year, with six of seven accounts exceeding 75% year-over-year growth [30][31] Question: Drivers of clonoSEQ volume growth and weather impact - Management confirmed no notable weather impacts and attributed growth to DLBCL and MCL, along with EMR integrations [36][37] Question: Milestone payments and funnel growth - Management indicated that more milestones are becoming available, providing clarity and confidence in the 2025 outlook [41][43] Question: Pricing and contracting discussions - Management emphasized discipline in pricing, ensuring contracted rates are close to Medicare rates [45][46] Question: Multiple myeloma trials and testing intervals - Management acknowledged increased interest in more frequent testing, particularly in multiple myeloma and other indications [50][52] Question: Technology improvements and addressing market adjacencies - Management is actively looking for ways to enhance technology and improve sensitivity in assays [54][56] Question: EMR integration and operational efficiencies - Management noted potential operational efficiencies from EMR integrations, with significant reductions in callbacks reported [60][61] Question: NeoGenomics partnership progress - Management provided updates on the selection of phase one accounts and preparations for the pilot launch in the second half of the year [106][108]

Kura Oncology (KURA) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Please standby. Your program is about to begin. If you need assistance during your conference today, please press 0. Good day everyone and welcome to today's First Quarter twenty twenty five CURA Oncology Financial Results Conference Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any t ...

Financial Data and Key Metrics Changes - The company reported net product sales of $75.9 million for Q1 2025, representing a 90% increase year-over-year and continued sequential growth [27] - Net sales for VILSPARI grew 182% year-over-year and 13% compared to the previous quarter, reflecting strong demand and uptake [6][20] - The net loss for Q1 2025 was $41.2 million, or $0.47 per basic share, compared to a net loss of $136.1 million, or $1.76 per basic share, for the same period in 2024 [32] Business Line Data and Key Metrics Changes - VILSPARI maintained strong momentum with $55.9 million in net product sales for Q1 2025, despite higher gross-to-net discounts due to insurance coverage changes [27][28] - Thiola and Thiola EC contributed $20 million in net product sales for the first quarter [28] - The company expects to receive a $17.5 million milestone payment from CSL V4 due to the conversion of VILSPARI's conditional approval to full approval in Europe [32] Market Data and Key Metrics Changes - The European Commission and MHRA in the UK converted FILSPARI's conditional approvals to full approvals for the treatment of adults with IgA nephropathy, enabling broader access across Europe and the UK [7] - Approximately 75% of nephrologists are now targeting proteinuria below 0.5 grams per gram, with nearly a third targeting even more ambitious goals of 0.3 grams [25] Company Strategy and Development Direction - The company aims to solidify VILSPARI's foundational positioning in IgA nephropathy and unlock additional growth through a potential new indication in FSGS [5] - The company is preparing for a potential launch of VILSPARI for FSGS, which is expected to be a significant opportunity, potentially larger than in IgA nephropathy [10][26] - The company is committed to advancing its investigational therapy PEG T for classical homocystinuria (HCU) and plans to restart patient enrollment in the Phase III HARMONY study next year [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategy with strong fundamentals and a clear focus on executing key priorities [11] - The company anticipates continued strong demand for FILSPARI and IgA nephropathy, projecting meaningful growth in net product sales throughout the year [33] - Management is monitoring legislative developments and geopolitical uncertainties but believes that potential tariffs on pharmaceutical products would not have a material impact on VILSPARI [33] Other Important Information - The company reported a decrease in R&D expenses to $46.9 million for Q1 2025, down from $49.4 million in the same period in 2024 [29] - Selling, general, and administrative expenses increased to $72.8 million for Q1 2025, compared to $64.2 million for the same period in 2024, largely due to increased investment in the FILSPARI launch [30] Q&A Session Summary Question: Can you elaborate on any interactions with the agency regarding the sNDA for FSGS? - Management indicated that interactions with the FDA have been consistent and progressing as expected, similar to previous experiences with the IGAN indication [36][38] Question: What do you think the label for FSGS will look like? - The expectation is that the indication will be for the treatment of FSGS in patients ages eight and up, based on the broad inclusion criteria of the duplex study [42][45] Question: How is the recent approval of Novartis' therapy impacting your sales reps in the field? - Management noted that it is early to assess the impact, but continued demand for FILSPARI has been observed, indicating confidence in its efficacy profile [50][52] Question: What is the impact of the removal of the REMS program on new patient starts in IGAN? - Management stated that REMS has not been an obstacle to performance and anticipates that modifications will enhance convenience for patients and physicians [76][78] Question: What is the split between new versus repeat prescribers for FILSPARI? - The split is slightly skewed towards experienced prescribers, with a healthy continuation of new prescribers as well [86]

Financial Data and Key Metrics Changes - In the first quarter, Las Vegas operations achieved net revenue of $495 million, up 1.9% year-over-year, and adjusted EBITDA of $235.9 million, up 2.7% year-over-year [7][8] - Consolidated net revenue for the first quarter was $497.9 million, an increase of 1.8% from the previous year, with adjusted EBITDA of $215.1 million, up 2.8% year-over-year [8] - The adjusted EBITDA margin for Las Vegas operations was 47.7%, an increase of 34 basis points, while the consolidated adjusted EBITDA margin was 43.2%, up 42 basis points [7][8] Business Line Data and Key Metrics Changes - The hotel division recorded its second highest first quarter revenue and profit, driven by increased occupancy [9] - The food and beverage division achieved near record performance, supported by higher cover counts across outlets [9] - Group sales and catering faced challenges but are expected to improve throughout 2025 [10] Market Data and Key Metrics Changes - The Durango Casino Resort has added over 95,000 new customers to the database and is on track to become one of the highest margin properties, generating a return net of cannibalization of nearly 16% [4][5] - The Las Vegas Valley is projected to add approximately 34,000 new households due to demographic growth, particularly in Summerlin [5] Company Strategy and Development Direction - The company is focused on reinvesting in existing properties to enhance amenities while maintaining operational discipline [6] - Expansion plans for Durango include adding over 25,000 square feet of casino space and a new parking garage [5][6] - The company is also investing in Sunset Station and Green Valley Ranch properties to capture growth in Henderson [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business prospects moving forward, citing strong customer engagement and robust spending [10] - The company anticipates full revenue recovery from cannibalization effects over the next couple of years [5] - Management highlighted the resilience of the Las Vegas locals market, which has historically performed well during recessions [38] Other Important Information - The company declared a special cash dividend of $1 per Class A common share, reflecting confidence in the business model and market resilience [17] - Capital expenditures for 2025 are expected to be between $350 million and $400 million, down $25 million from previous estimates [12] Q&A Session Summary Question: OpEx growth and flow-through in Las Vegas - Management noted subdued OpEx growth with a flow-through above 60%, attributed to better sports win performance and flat COGS [20][22] Question: Backfill efforts at Red Rock - Management indicated that cannibalization is expected to be about 10% and they are ahead of schedule in backfilling revenue [27] Question: Special dividend and capital allocation - The special dividend reflects a balanced approach to long-term growth and shareholder returns, with ongoing evaluations of capital allocation [32][34] Question: Resilience of the Las Vegas locals market - Management emphasized the market's resilience during past recessions and its ability to maintain consistent visitation [38] Question: Construction environment and cost management - Management is actively managing procurement to mitigate impacts from tariffs and expects minimal material impact on current projects [42][48] Question: Non-gaming spend trends - Non-gaming spend remains stable, with food and beverage covers up despite slight revenue decline [78][80] Question: California-based customer demand - Management reported stable visitation from California, with gas prices making travel to Las Vegas still affordable [91][92]

Exponent (EXPO) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Exponent, Inc. First Quarter twenty twenty five Earnings Conference Call. All participants will be in the listen only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on your telephone keypad. To withdraw your question, please press then 2. Please note this event is being recorded. I would now like to turn the conference over to Jon ...

NV5 Global (NVEE) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and thank you for participating in today's conference call to discuss NV5's financial results for the first quarter twenty twenty five ended 03/29/2025. Joining us today are Dickerson Wright, Executive Chairman of NV5 Ben Hurad, CEO of NV5 Edward Codispoti, CFO of NV5 and Richard Tong, Executive Vice President and General Counsel at NV5. I would now like to turn the call over to Richard Tong. Speaker1 Thank y ...

Airbnb (ABNB) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and thank you for joining Airbnb's Earnings Conference Call for the First Quarter of twenty twenty five. As a reminder, this conference call is being recorded and will be available for replay from the Investor Relations section Speaker1 of Speaker0 Airbnb's website following this call. I will now hand the call over to Angela Yang, Director of Investor Relations. Please go ahead. Speaker2 Good afternoon, and welcome to Airb ...

iRhythm (IRTC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 afternoon. Thank you for attending the iRhythm Technologies Inc. First Quarter twenty twenty five Earnings Conference Call. My name is Cameron, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. Again, due to the interest of time, we ask that you ask one question and to re queue for any follow-up questions. I would now like to ...